Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
Primary Purpose
Vascular Disease, Peripheral
Status
Unknown status
Phase
Early Phase 1
Locations
Chile
Study Type
Interventional
Intervention
Endovascular Intervention
Sponsored by
About this trial
This is an interventional treatment trial for Vascular Disease, Peripheral
Eligibility Criteria
Inclusion Criteria:
- Patient with claudication or ischemic rest pain(Rutherford Categories 2-4)
- The angiogram will need to have been performed confirming superficial femoral artery short segment occlusion(<5cm first two patients and <10cm there on) or high grade(>50%)stenosis
- Patient has a signed and dated informed consent
- Patient has a resting ABI <0.9 or an abnormal exercise ABI if resting ABI is normal. Patients with incompressible arteries (ABI >1.2) must have TBI <0.8
- Life expectancy greater than one year
- The ability to comply with protocol follow up requirements and required testing
Angiographic lesion requirements assessed at time of procedure
- Lesion of the superficial femoral artery with a short segment occlusion(<5cm first two patients and <10cm there on) or high grade (>50%) stenosis
- Target lesion 1 cm below profunda/superficial femoral artery origin and 3cm above knee joint
- Angiographic evidence of a minimum of at least one tibial with continuous artery runoff to the ankle that does not require intervention
- Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel, and successful placement of 9 french(Fr) sheath
Exclusion Criteria:
- Untreated iliac artery in-flow limiting lesion
- Significant proximal common femoral or superficial femoral artery disease above or below target lesion
- Any previously treated superficial femoral artery lesion
- Any previous stenting or surgery in the target vessel
- Femoral or popliteal aneurysm
- Non-Atherosclerotic disease resulting in occlusion (e.g. embolism, vasculitis,etc)
- Serum creatinine >2.5 mg/dl
- Any previously known coagulation disorder, including hypercoagulability
- Severe medical co-morbidities or other medical condition (for example untreated coronary heart disease and congestive heart failure, severe chronic obstructive pulmonary disease, metastasis malignance, etc.)
Sites / Locations
- Pontificia Universidad Catolica de ChileRecruiting
Outcomes
Primary Outcome Measures
Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events
Secondary Outcome Measures
Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization
Full Information
NCT ID
NCT00542646
First Posted
October 10, 2007
Last Updated
November 27, 2007
Sponsor
PeriTec Biosciences Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT00542646
Brief Title
Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
Official Title
Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
Study Type
Interventional
2. Study Status
Record Verification Date
November 2007
Overall Recruitment Status
Unknown status
Study Start Date
November 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
PeriTec Biosciences Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The occurrence of Peripheral Vascular Disease has been increasing which includes the large artery in the upper leg called Superficial Femoral Artery (SFA). The Peritoneal Lined Stent has been developed as a new method for treating narrowed area in the SFA. This research study will determine the safety and effectiveness of the Peritoneal Lined Stent in keeping th Superficial Femoral Artery open and allowing blood to flow in the leg.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vascular Disease, Peripheral
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
45 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Endovascular Intervention
Intervention Description
Peritoneal Lined Stent Endovascular Intervention
Primary Outcome Measure Information:
Title
Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization
Time Frame
3 Months Intervals except for Target Lesion Revascularization at 12 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with claudication or ischemic rest pain(Rutherford Categories 2-4)
The angiogram will need to have been performed confirming superficial femoral artery short segment occlusion(<5cm first two patients and <10cm there on) or high grade(>50%)stenosis
Patient has a signed and dated informed consent
Patient has a resting ABI <0.9 or an abnormal exercise ABI if resting ABI is normal. Patients with incompressible arteries (ABI >1.2) must have TBI <0.8
Life expectancy greater than one year
The ability to comply with protocol follow up requirements and required testing
Angiographic lesion requirements assessed at time of procedure
Lesion of the superficial femoral artery with a short segment occlusion(<5cm first two patients and <10cm there on) or high grade (>50%) stenosis
Target lesion 1 cm below profunda/superficial femoral artery origin and 3cm above knee joint
Angiographic evidence of a minimum of at least one tibial with continuous artery runoff to the ankle that does not require intervention
Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel, and successful placement of 9 french(Fr) sheath
Exclusion Criteria:
Untreated iliac artery in-flow limiting lesion
Significant proximal common femoral or superficial femoral artery disease above or below target lesion
Any previously treated superficial femoral artery lesion
Any previous stenting or surgery in the target vessel
Femoral or popliteal aneurysm
Non-Atherosclerotic disease resulting in occlusion (e.g. embolism, vasculitis,etc)
Serum creatinine >2.5 mg/dl
Any previously known coagulation disorder, including hypercoagulability
Severe medical co-morbidities or other medical condition (for example untreated coronary heart disease and congestive heart failure, severe chronic obstructive pulmonary disease, metastasis malignance, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rajesh Khosla, MBA
Phone
216.444.1293
Email
rkhosla@peritecbio.com
First Name & Middle Initial & Last Name or Official Title & Degree
Linda Modzelewski
Phone
216.444.5004
Email
lm@peritecbio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timur Sarac, MD
Organizational Affiliation
PeriTec Bioscience Ltd
Official's Role
Study Director
Facility Information:
Facility Name
Pontificia Universidad Catolica de Chile
City
Santiago
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Albrecht Kramer, MD
Phone
562.354.3233
Email
kramer@med.puc.cl
12. IPD Sharing Statement
Citations:
PubMed Identifier
16643070
Citation
Carnevale K, Ouriel K, Gabriel Y, Clair D, Bena JF, Silva MB, Sarac TP. Biological coating for arterial stents: the next evolutionary change in stents. J Endovasc Ther. 2006 Apr;13(2):164-74. doi: 10.1583/05-1710R.1.
Results Reference
background
PubMed Identifier
15838485
Citation
Sarac TP, Carnevale K, Smedira N, Tanquilut E, Augustinos P, Patel A, Naska T, Clair D, Ouriel K. In vivo and mechanical properties of peritoneum/fascia as a novel arterial substitute. J Vasc Surg. 2005 Mar;41(3):490-7. doi: 10.1016/j.jvs.2004.11.033.
Results Reference
background
Learn more about this trial
Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
We'll reach out to this number within 24 hrs